Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $57 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $57 price target.
byBenzinga Newsdesk
March 1, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $57 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Veeco Instruments Inc Expects Q4 Revenue of $165M-$175M (Prior $155M-$175M) ($167.17M Est), Adj EPS $0.40-$0.45 (Prior $0.35-$0.45) ($0.41 Est), FY23 Revenue $658M-$668M, Adj EPS $1.58-$1.65, FY24 Revenue $680M-$740M, Adj EPS $1.60-$1.90

By Benzinga Newsdesk
January 17, 8:38 AM
Veeco Instruments Inc. (NASDAQ:VECO) today has updated its financial guidance for the fourth quarter of 2023 and provided an initial 2024 outlook. Veeco's management is scheduled to meet

VECO